Delavirdine susceptibilities and associated reverse transcriptase mutations in human immunodeficiency virus type 1 isolates from patients in a phase I/II trial of delavirdine monotherapy (ACTG 260).

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples